The Effect of Trimebutine Maleate in Capsule Enteroscopy

The Effect of Trimebutine Maleate in Capsule Enteroscopy - The Effect of Trimebutine Maleate in Capsule Enteroscopy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030534

Enrollment

Registered

2017-12-23

Start date

2017-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small bowel disease

Interventions

the trimebutine maleate group the control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who underwent CE patients who had Chronic gastritis or Irritable bowel syndrome

Exclusion criteria

Exclusion criteria: Severe liver dysfunction, pregnancy, Patients taking of trimebutine maleate at registration

Design outcomes

Primary

Measure	Time frame
Gastrointestinal transit time of capsule endoscopy.	—

Secondary

Measure	Time frame
diagnostic yield of capsule endoscopy. Field of clearly view in the gastrointestinal tract.	—

Countries

Japan

Contacts

Public ContactRyu Nishiyama

Hiratsuka kyosai hospital Department of Gastroenterology

ryuwest@jcom.zaq.ne.jp0463-32-1950

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026